We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Immix Biopharma Inc (IMMX) USD0.0001

Sell:$3.07 Buy:$3.15 Change: $0.08 (2.61%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.07
Buy:$3.15
Change: $0.08 (2.61%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$3.07
Buy:$3.15
Change: $0.08 (2.61%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a class of Tissue-Specific Therapeutics (TSTx) in oncology and inflammation. Its lead asset, IMX-110, is in Phase Ib/IIa clinical trials for solid tumors in the United States and Australia. IMX-110 is a negatively charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor (which inhibits multiple kinases simultaneously) and induces tumor cell death with an apoptosis inducer (which activates apoptosis, a non-inflammatory programmed cell death pathway), leveraging its TME Normalization Technology, delivered deep into the tumor micro-environment (TME). Its TME Normalization Technology allows its drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its other drug candidates include IMX-111 and IMX-120. IMX-111 and IMX-120 are under development for colorectal cancer and inflammatory bowel disease.

Contact details

Address:
11400 West Olympic Blvd., Suite 200
LOS ANGELES
90064
United States
Telephone:
+1 (310) 6518041
Website:
https://immixbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IMMX
ISIN:
US45258H1068
Market cap:
$77.19 million
Shares in issue:
25.14 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Ilya Rachman
    Chairman of the Board, Chief Executive Officer
  • Vladimir Torchilin
    Scientific Co-Founder
  • Gabriel Morris
    Chief Financial Officer, Director
  • Nandan Oza
    Head - Chemistry, Manufacturing, and Control
  • Graham Ross
    Acting Chief Medical Officer, Head - Clinical Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.